Clinical Trial Update: Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®

View source ↗

Summary

Clinical trial update for Synagis Liquid 50mg and 100mg for intramuscular injection in immunocompromised children with Respiratory Syncytial Virus infection; st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: AbbVie | Conditions: Respiratory Syncytial Virus Infection | Status: COMPLETED | Results posted: 2017-02-08